Jeffrey Evans

551 total citations
6 papers, 421 citations indexed

About

Jeffrey Evans is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jeffrey Evans has authored 6 papers receiving a total of 421 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jeffrey Evans's work include Cancer therapeutics and mechanisms (2 papers), DNA Repair Mechanisms (2 papers) and PARP inhibition in cancer therapy (2 papers). Jeffrey Evans is often cited by papers focused on Cancer therapeutics and mechanisms (2 papers), DNA Repair Mechanisms (2 papers) and PARP inhibition in cancer therapy (2 papers). Jeffrey Evans collaborates with scholars based in United Kingdom, United States and France. Jeffrey Evans's co-authors include Ruth Plummer, Mark R. Middleton, Christopher J. Jones, L Robson, Heidi Steinfeldt, Adrian L. Harris, Richard H. Wilson, Peter J. McHugh, Patrick S. Johnson and Alan V. Boddy and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Journal of Translational Medicine.

In The Last Decade

Jeffrey Evans

6 papers receiving 416 citations

Peers

Jeffrey Evans

ONCOL

MB

IMMUN

EEE

GENET

Marta Castroviejo‐Bermejo Spain

Ruud van der Noll Netherlands

R. Dewji United Kingdom

Kyung-Hun Lee South Korea

Kathleen A. Bridges United States

Jay Y. Spiegel United States

Tabari M. Baker United States

Robert J. Cardnell United States

Dana‐Adriana Botesteanu United States

S. M. Domchek United States

Marta Castroviejo‐Bermejo Spain

Jeffrey Evans

395 ×1.2

ONCOL

286 ×1.0

MB

55 ×1.0

IMMUN

52 ×1.0

EEE

70 ×2.0

GENET

Citations per year, relative to Jeffrey Evans Jeffrey Evans (= 1×) peers Marta Castroviejo‐Bermejo

Countries citing papers authored by Jeffrey Evans

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Evans more than expected).

Fields of papers citing papers by Jeffrey Evans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Evans. The network helps show where Jeffrey Evans may publish in the future.

Co-authorship network of co-authors of Jeffrey Evans

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Evans. A scholar is included among the top collaborators of Jeffrey Evans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Evans. Jeffrey Evans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Cruz‐Merino, Luis de la, Lorenza Di Guardo, Jean‐Jacques Grob, et al.. (2017). Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. Journal of Translational Medicine. 15(1). 146–146. 30 indexed citations

2.

Moreno, Víctor, David Olmos, Carlos Gomez‐Roca, et al.. (2014). Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study. Clinical Cancer Research. 20(22). 5663–5671. 14 indexed citations

3.

Mitchell, Claire L., James P.B. O’Connor, Caleb Roberts, et al.. (2010). A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemotherapy and Pharmacology. 68(3). 631–641. 19 indexed citations

4.

Plummer, Ruth, Christopher J. Jones, Mark R. Middleton, et al.. (2008). Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors. Clinical Cancer Research. 14(23). 7917–7923. 298 indexed citations

5.

Hawkins, David & Jeffrey Evans. (2005). Minimising the risk of heparin-induced osteoporosis during pregnancy. Expert Opinion on Drug Safety. 4(3). 583–590. 23 indexed citations

6.

Plummer, Ruth, Mark R. Middleton, R. Wilson, et al.. (2005). First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 23(16_suppl). 3065–3065. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact